The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy
Camidge and Lewis Discuss the Perspective of Being Both a Patient and Physician
FDA Approves Noninvasive Stool RNA Screening Test for CRC
Agnostic Approval of Trastuzumab Deruxtecan Ushers in New Option for Advanced HER2+ Solid Tumors
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer